123 related articles for article (PubMed ID: 36876839)
1. Knockdown of Programmed Death 1 Inhibited Progression of Papillary Thyroid Carcinoma in Mice.
Wang H; Chu Q; Ma S; Tao Y
Protein Pept Lett; 2023; 30(5):396-400. PubMed ID: 36876839
[TBL] [Abstract][Full Text] [Related]
2. CKS1B promotes cell proliferation and invasion by activating STAT3/PD-L1 and phosphorylation of Akt signaling in papillary thyroid carcinoma.
Wang H; Zhang Z; Yan Z; Ma S
J Clin Lab Anal; 2021 Jan; 35(1):e23565. PubMed ID: 32960462
[TBL] [Abstract][Full Text] [Related]
3. Programmed Death-Ligand 1 Expression in Papillary Thyroid Cancer and Its Correlation with Clinicopathologic Factors and Recurrence.
Shi RL; Qu N; Luo TX; Xiang J; Liao T; Sun GH; Wang Y; Wang YL; Huang CP; Ji QH
Thyroid; 2017 Apr; 27(4):537-545. PubMed ID: 27825291
[TBL] [Abstract][Full Text] [Related]
4. Papillary Thyroid Carcinoma Emerging from Hashimoto Thyroiditis Demonstrates Increased PD-L1 Expression, Which Persists with Metastasis.
Lubin D; Baraban E; Lisby A; Jalali-Farahani S; Zhang P; Livolsi V
Endocr Pathol; 2018 Dec; 29(4):317-323. PubMed ID: 30121940
[TBL] [Abstract][Full Text] [Related]
5. PD1 Blockade Enhances ICAM1-Directed CAR T Therapeutic Efficacy in Advanced Thyroid Cancer.
Gray KD; McCloskey JE; Vedvyas Y; Kalloo OR; Eshaky SE; Yang Y; Shevlin E; Zaman M; Ullmann TM; Liang H; Stefanova D; Christos PJ; Scognamiglio T; Tassler AB; Zarnegar R; Fahey TJ; Jin MM; Min IM
Clin Cancer Res; 2020 Nov; 26(22):6003-6016. PubMed ID: 32887724
[TBL] [Abstract][Full Text] [Related]
6. Interleukin 6 regulates the expression of programmed cell death ligand 1 in thyroid cancer.
Zhang GQ; Jiao Q; Shen CT; Song HJ; Zhang HZ; Qiu ZL; Luo QY
Cancer Sci; 2021 Mar; 112(3):997-1010. PubMed ID: 33247999
[TBL] [Abstract][Full Text] [Related]
7. PD-L1, PDK-1 and p-Akt are correlated in patients with papillary thyroid carcinoma.
Wang H; Zhang Z; Yan Z; Ma S
Adv Clin Exp Med; 2020 Jul; 29(7):785-792. PubMed ID: 32750756
[TBL] [Abstract][Full Text] [Related]
8. PD-L1 expression in papillary thyroid cancer with and without lymphocytic thyroiditis: a cross sectional study.
Fadia M; Fookeerah P; Ali S; Shadbolt B; Greenaway T; Perampalam S
Pathology; 2020 Apr; 52(3):318-322. PubMed ID: 32107082
[TBL] [Abstract][Full Text] [Related]
9. PD-L1 expression in rare and aggressive thyroid cancers: A preliminary investigation for a role of immunotherapy.
Boruah M; Gaddam P; Agarwal S; Mir RA; Gupta R; Sharma MC; S Deo SV; Nilima N
J Cancer Res Ther; 2023; 19(2):312-320. PubMed ID: 37006068
[TBL] [Abstract][Full Text] [Related]
10. PD-L1 and thyroid cytology: A possible diagnostic and prognostic marker.
Dell'Aquila M; Granitto A; Martini M; Capodimonti S; Cocomazzi A; Musarra T; Fiorentino V; Pontecorvi A; Lombardi CP; Fadda G; Pantanowitz L; Larocca LM; Rossi ED
Cancer Cytopathol; 2020 Mar; 128(3):177-189. PubMed ID: 31821747
[TBL] [Abstract][Full Text] [Related]
11. Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants.
Chowdhury S; Veyhl J; Jessa F; Polyakova O; Alenzi A; MacMillan C; Ralhan R; Walfish PG
Oncotarget; 2016 May; 7(22):32318-28. PubMed ID: 27086918
[TBL] [Abstract][Full Text] [Related]
12. PD-L1 and PD-1 expression in thyroid follicular epithelial dysplasia: Hashimoto thyroiditis related atypia and potential papillary carcinoma precursor.
Pakkanen E; Kalfert D; Ahtiainen M; Ludvíková M; Kuopio T; Kholová I
APMIS; 2022 May; 130(5):276-283. PubMed ID: 35238073
[TBL] [Abstract][Full Text] [Related]
13. RETRACTED: KDM5B-mediated microRNA-448 up-regulation restrains papillary thyroid cancer cell progression and slows down tumor growth via TGIF1 repression.
Pu Y; Xiang J; Zhang J
Life Sci; 2020 Jun; 250():117519. PubMed ID: 32147429
[TBL] [Abstract][Full Text] [Related]
14. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer.
Mehnert JM; Varga A; Brose MS; Aggarwal RR; Lin CC; Prawira A; de Braud F; Tamura K; Doi T; Piha-Paul SA; Gilbert J; Saraf S; Thanigaimani P; Cheng JD; Keam B
BMC Cancer; 2019 Mar; 19(1):196. PubMed ID: 30832606
[TBL] [Abstract][Full Text] [Related]
15. Oncogenic Ras/squamous cell carcinoma antigen signaling pathway activation promotes invasiveness and lymph node metastases in papillary thyroid carcinoma.
Luo D; Liu Y; Lin S; Tan L; Du Z; Long M; Zhu Y; Peng X; Zong W; Mackenzie GG; Li H; Ouyang N
Oncol Rep; 2019 Feb; 41(2):1253-1263. PubMed ID: 30535496
[TBL] [Abstract][Full Text] [Related]
16. Programmed Death-Ligand 1 (PD-L1) Is a Potential Biomarker of Disease-Free Survival in Papillary Thyroid Carcinoma: a Systematic Review and Meta-Analysis of PD-L1 Immunoexpression in Follicular Epithelial Derived Thyroid Carcinoma.
Girolami I; Pantanowitz L; Mete O; Brunelli M; Marletta S; Colato C; Trimboli P; Crescenzi A; Bongiovanni M; Barbareschi M; Eccher A
Endocr Pathol; 2020 Sep; 31(3):291-300. PubMed ID: 32468210
[TBL] [Abstract][Full Text] [Related]
17. IL-10 Restores MHC Class I Expression and Interferes With Immunity in Papillary Thyroid Cancer With Hashimoto Thyroiditis.
Lu ZW; Hu JQ; Liu WL; Wen D; Wei WJ; Wang YL; Wang Y; Liao T; Ji QH
Endocrinology; 2020 Oct; 161(10):. PubMed ID: 32348468
[TBL] [Abstract][Full Text] [Related]
18. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
19. Role of cytotoxic T cells and PD-1 immune checkpoint pathway in papillary thyroid carcinoma.
Banerjee S; Nahar U; Dahiya D; Mukherjee S; Dey P; Gupta R; Radotra B; Sachdeva N; Sood A; Bhadada SK; Bhansali A
Front Endocrinol (Lausanne); 2022; 13():931647. PubMed ID: 36518249
[TBL] [Abstract][Full Text] [Related]
20. PD-L1 and PD-1 expression are correlated with distinctive clinicopathological features in papillary thyroid carcinoma.
Bai Y; Niu D; Huang X; Jia L; Kang Q; Dou F; Ji X; Xue W; Liu Y; Li Z; Feng Q; Lin D; Kakudo K
Diagn Pathol; 2017 Oct; 12(1):72. PubMed ID: 28974264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
